



July 24, 2020

The Honorable TJ Donovan  
Attorney General  
State of Vermont  
109 State Street  
Montpelier, VT 05609

Sent via e-mail to [AGO.DrugCosts@vermont.gov](mailto:AGO.DrugCosts@vermont.gov)

Dear Attorney General Donovan,

As follow-up to our notification sent on June 25, 2020, and per 18 V.S.A. § 4637(c), Allergan is providing the following information related to the launch of DURYSTA™ (bimatoprost implant). Per 18 V.S.A. § 4637(d), the information provided below is limited to information that is in the public domain or publicly available.

- 1) A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally;
  - DURYSTA will be marketed to adults for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).
  - The Wholesale Acquisition Cost (WAC) of DURYSTA is \$1950 per implant.
  - To date Allergan has not filed for regulatory approval of DURYSTA in jurisdictions outside the United States.

- 2) The estimated volume of patients who may be prescribed the drug

DURYSTA is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). A 2012 published study identified 2.71 million patients in the US with open angle glaucoma and projected greater than 3 million patients in 2020. See Vajaranant, T et al., The Changing Face of Primary Open-Angle Glaucoma in the United States: Demographic and Geographic Changes From 2011 to 2050, *Am. J. of Ophthalmology*, 154:303-314 (2012). See also Glaucoma Research Foundation website, at <https://www.glaucoma.org/glaucoma/glaucoma-facts-and-stats.php>. DURYSTA may be prescribed for that fraction of patients for whom a physician and patient in consultation may consider this treatment appropriate.

- 3) Breakthrough therapy designation or priority review by FDA

DURYSTA was not granted breakthrough designation or priority review by the FDA.



4) Date and price of acquisition, if the drug was not developed by the manufacturer

DURYSTA was developed by Allergan. On May 8, 2020 AbbVie Inc. completed its acquisition of Allergan plc at a cost of approximately \$63 billion.

Sincerely,

Doug Fernandes

Vice President Payer Marketing and Pricing

abbvie

5 Giralda Farms

Madison, NJ 07940

[PriceDisclosure@allergan.com](mailto:PriceDisclosure@allergan.com)

